Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Healthcare Company (ACHC) Gains from Sales and Divestitures (2016 - 2026)

Acadia Healthcare Company (ACHC) has disclosed Gains from Sales and Divestitures for 15 consecutive years, with $56425.0 as the latest value for Q1 2026.

  • For Q1 2026, Gains from Sales and Divestitures fell 15.37% year-over-year to $56425.0; the TTM value through Mar 2026 reached $56425.0, down 15.37%, while the annual FY2025 figure was $457275.0, 364.22% up from the prior year.
  • Gains from Sales and Divestitures hit $56425.0 in Q1 2026 for Acadia Healthcare Company, down from $457275.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.4 million in Q2 2023 and bottomed at $56425.0 in Q1 2026.
  • Average Gains from Sales and Divestitures over 5 years is $416894.5, with a median of $342259.0 recorded in 2024.
  • Year-over-year, Gains from Sales and Divestitures plummeted 93.0% in 2024 and then skyrocketed 364.22% in 2025.
  • Acadia Healthcare Company's Gains from Sales and Divestitures stood at $518474.0 in 2022, then fell by 22.23% to $403223.0 in 2023, then crashed by 75.57% to $98504.0 in 2024, then surged by 364.22% to $457275.0 in 2025, then crashed by 87.66% to $56425.0 in 2026.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $56425.0, $457275.0, and $66676.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.